Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

NCT ID: NCT06840704

Last Updated: 2025-02-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 121 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-25
• Study Completion Date: 2026-06-30

Brief Summary

This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.

Detailed Description

This is a prospective, randomized, controlled, open-label clinical trial, which aimed to explore the efficacy and safety of oral immunonutrition therapy in reducing acute esophagitis after thoracic radiotherapy in lung cancer patients.

Conditions

Non Small Cell Lung Cancer; Small Cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Oral immunonutrition

Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.

Group Type: EXPERIMENTAL

Oral immunonutrition

Intervention Type: DIETARY_SUPPLEMENT

Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.

Standard nutrition

If the patient has concurrent nutritional risks, routine nutritional therapy (no immunonutrition) can be provided under the guidance of a nutritionist.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Oral immunonutrition

Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. The subject voluntarily participates in this clinical study, understands the study procedures, and is able to provide written informed consent.

2. Age ≥ 18 years.

3. Pathologically confirmed diagnosis of lung cancer, including non-small cell lung cancer and small cell lung cancer.

4. Indication for thoracic radiotherapy, with the esophagus within 1 cm of the PTV.

5. Prescription dose for the PTV: 60-70 Gy once daily (2 Gy/Fx), 45 Gy twice daily (1.5 Gy/Fx, with intervals exceeding 6 hours), or 45 Gy once daily (3 Gy/Fx).

6. Ability to orally intake food normally.

7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

8. The volume of both lungs receiving more than 20 Gy (V20) should not exceed 30% of the total lung volume.

9. Expected survival of more than 3 months.

10. Laboratory test results during the screening period:

Complete blood count: ANC ≥ 1.5 × 10^9/L; PLT ≥ 80 × 10^9/L; Hb ≥ 90 g/L. Blood biochemistry: TBIL ≤ 1.5 × ULN; ALT and AST ≤ 2 × ULN; BUN and Cr ≤ 1.5 × ULN, with creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula).

11. Female subjects of childbearing potential, male subjects, and partners of male subjects agree to use reliable contraceptive methods during the study period (such as abstinence, sterilization, oral contraceptives, or other contraceptive measures).

Exclusion Criteria

1. Previous history of thoracic radiotherapy.

2. Suspected or confirmed tumor invasion of the esophagus.

3. Patients with other primary tumors.

4. History of esophageal cancer, gastric cancer, or prior esophageal surgery.

5. Concurrent active reflux esophagitis.

6. Current regular use of immunonutrition (e.g., Oral Impact®).

7. Patients with severe cardiovascular or cerebrovascular diseases, or comorbidities such as liver or kidney diseases.

8. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.

9. Concurrent active autoimmune diseases requiring treatment.

10. Known history of human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS).

11. Any medical (e.g., pulmonary, metabolic, endocrine, or neurological diseases, congenital disorders, etc.), psychiatric, or social condition that, in the investigator's judgment, may interfere with the subject's rights, safety, health, or ability to provide informed consent, cooperate and participate in the study, or interfere with the evaluation of the study drug, interpretation of patient safety, or study results.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hunan Cancer Hospital

OTHER

Sponsor Role: lead

Responsible Party

HuaiLiu

Prof.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Huai Liu, M.D.

Role: PRINCIPAL_INVESTIGATOR

Hunan Cancer Hospital

Locations

Hunan Cancer Hospital

Changsha, Hunan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Huai Liu, M.D.

Role: CONTACT

liuhuai@hnca.org.cn

+8673189762230

Facility Contacts

Huai Liu, M.D.

Role: primary

liuhuai@hnca.org.cn

+8673189762230

Other Identifiers

IIT128

Identifier Type: -

Identifier Source: org_study_id